Document:

SECOND AMENDMENT TO RESTRUCTURING SUPPORT AGREEMENT

 Exhibit 10.8 
 SECOND AMENDMENT TO RESTRUCTURING SUPPORT 
 AGREEMENT 

This SECOND AMENDMENT TO RESTRUCTURING SUPPORT AGREEMENT (this “Amendment”), dated as of October 3,
2011, is by and between Horizon Lines, Inc. (the “Parent”), a corporation duly organized and existing under the laws of the State of Delaware, and all of its subsidiaries and any successors thereto (collectively with the Parent, the
“Company”) and the holder set forth on the signature page (the “Exchanging Holder”) of the 4.25% convertible senior notes due 2012 (the “Notes”) issued under the Indenture, dated as of
August 8, 2007 (as amended, supplemented, or modified from time to time, the “Indenture”), by and between the Parent, as issuer, and The Bank of New York Trust Company, N.A., as Trustee, in the aggregate principal amount of
$330,000,000.00. Capitalized terms not herein defined shall have the meanings set forth in the RSA (as defined below). 

RECITALS 
 WHEREAS, the Company and the Exchanging Holder are party to that certain Restructuring Support Agreement dated as of August 26, 2011 (as amended modified, or supplemented from time to time,
the “RSA”); and 
 WHEREAS, the Company has requested that the Exchanging Holder amend
the RSA and the Exchanging Holder has agreed to amend the RSA in accordance with and subject to the terms and conditions set forth herein. 
 AGREEMENT 
 NOW, THEREFORE, in consideration
of the agreements hereinafter set forth, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereto agree as follows: 

1. Amendments to the RSA. 
 1.1 Section 26 of the RSA is hereby amended and restated in its entirety as follows: 
 “Section 26. Corporate Governance and Management/Employee Incentive Plan 
 The Company acknowledges that the terms set forth in the Restructuring Term Sheet under the Headings “Corporate Governance” and “Management/Employee Incentive Plan” will not be
satisfied as of the Effective Date. As a result thereof, the Company covenants and agrees that it shall: 
 (i) with respect to those seven (7) candidates who will be designated by the Exchanging Holder(s) (each a “Holder Designee”) to the Company’s board of directors (the
“Board”, each director a “Director”), in the period between the closing of the Exchange Offer and the Effective 

 
Date, nominate and subsequently elect (subject to the Company’s customary due diligence process) all seven Holder Designees to the Board as promptly as possible after the Effective Date but,
in any event, by the earlier to occur of (x) October 27, 2011 and (y) the first meeting of the Company’s shareholders that occurs following the Effective Date (the “Meeting”); 

(ii) if any Holder Designee is not timely elected as set forth in clause (i) above, then the Company
shall nominate the Holder Designees as a slate of director candidates for approval by the shareholders at the Meeting (subject to the Company’s customary due diligence process); 

(iii) use reasonable best efforts to cause the Board to expand to comprise eleven (11) Directors;

 (iv) use reasonable best efforts to cause the Holder Designees to comprise a majority of
Directors of the Board at or prior to the Meeting; 
 (v) use reasonable best efforts to
implement a 1 to 25 reverse share split at the Meeting; 
 (vi) not adopt or propose any
management incentive plan or make any grants of stock, options or other compensation under any management incentive plan until such time as all of the appointments and other actions set forth in subclauses (i) and (ii) above shall have
been effectuated; provided, however, that any management incentive plan thereafter approved and implemented by the Company shall be consistent in all respects with the terms set forth in the Restructuring Term Sheet; 

(vii) if any Holder Designee is not elected to the Board at or prior to the Meeting, then the Holder
Designees who have been so elected as Directors shall nominate and elect one or more candidates as necessary for the Holder Designees elected pursuant to this subclause (vii), together with the Holder Designees elected pursuant to subclauses
(i) and (ii) above, to constitute a majority of Directors of the Board; and 
 (viii)
in the event the Board is unable to agree on the four existing Directors (excluding Holder Designees) to remain on the Board following the Effective Date, the Company shall use its reasonable best efforts to cause the terms of the existing Directors
in a class with the longest term expiry to terminate, it being understood, however that this clause (viii) shall not apply to the chairman of the Board in office as of the Effective Date. 

2. Effectiveness. In accordance with Section 16 of the RSA, this Amendment shall be effective and binding upon the Company
and the undersigned Exchanging Holder as of the date (the “Amendment Effective Date”) on which: (i) the Company shall have 

 
executed and delivered counterpart signature pages of this Amendment to counsel to the Exchanging Holders and (ii) at least two-thirds of the Exchanging Holders, each of which is a party to
a Similar RSA, shall have executed and delivered counterpart signature pages of this Amendment to counsel to the Company. 
 3.
Representations and Warranties. Each Party hereby represents and warrants that as of the Amendment Effective Date, the representations and warranties contained in Section 8 of the RSA are true and current in all material respects on and
as of Amendment Effective Date (and after giving pro forma effect to the Transactions) to the same extent as though made on and as of that date, except to the extent such representations and warranties specifically relate to an earlier date, in
which case such representations and warranties shall have been true and correct in all material respects on and as of such earlier date. 
 4. Effect Upon RSA. Except as specifically set forth herein, the RSA shall remain in full force and effect and is hereby ratified and confirmed. The parties hereto specifically acknowledge and
agree that the RSA, as hereby amended, is in full force and effect in accordance with its respective terms and has not been modified, except pursuant to this Amendment. This Amendment shall be deemed to be Definitive Documentation for all purposes
under and in connection with the RSA and the other Definitive Documentation and shall be binding upon and inure to the benefit of each of the parties hereto and their respective successors and assigns. All references to the “RSA” in the
Definitive Documentation shall mean and refer to the RSA, as modified by this Amendment. 
 5. Counterparts. This
Amendment may be executed in one or more counterparts, each of which, when so executed, shall constitute the same instrument and the counterparts may be delivered by facsimile transmission or by electronic mail in portable document format (.pdf).

 6. Headings. The headings of the sections, paragraphs and subsections of this Amendment are inserted for convenience
only and shall not affect the interpretation hereof. 
 7. Governing Law. This Amendment shall be governed by, and
construed in accordance with, the laws of the State of New York, without regard to such state’s choice of law provisions which would require the application of the law of any other jurisdiction. 

 IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized
officers to execute and deliver this Amendment as of the date first above written. 
  

					
	 HORIZON LINES, INC.

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 HORIZON LINES HOLDING CORP.

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 HORIZON LINES, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 HORIZON LINES OF PUERTO RICO, INC.

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 HAWAII STEVEDORES, INC.

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	

  
 Signature
Page to Second Amendment to Restructuring 
 Support Agreement 

					
	
	 HORIZON LOGISTICS, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 H-L DISTRIBUTION SERVICE, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 HORIZON LINES OF ALASKA, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 HORIZON LINES OF GUAM, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 HORIZON LINES VESSELS, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	

  
 Signature
Page to Second Amendment to Restructuring 
 Support Agreement 

					
	
	 SEA-LOGIX, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 AERO LOGISTICS, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	
	
	 HORIZON SERVICES GROUP, LLC

		
	 By:
	 	  

		 	 Name:
	 	
		 	 Title:
	 	

  
 Signature
Page to Second Amendment to Restructuring 
 Support Agreement 

					
	
	 EXCHANGING HOLDER:

	
	 [INSERT NAME OF EXCHANGING HOLDER ]

		
	 By:
	 	  

		 	 Name:
	 	  

		 	 Title:
	 	  

  
 Signature
Page to Second Amendment to Restructuring 
 Support AgreementConsulting and Separation Agreement

 Exhibit 10.1 
 

 
  

									
		 		  		  	 James C. Mullen

Chief Executive Officer
 Patheon
Inc.
 U.S. Headquarters

4721 Emperor Blvd., Suite 200

Durham, North Carolina 27703
	  	

 October 4, 2011 
 PRIVATE AND CONFIDENTIAL 
 Peter T. Bigelow 

60 Diamond Road 
 Phoenixville, PA 19460-2780

 RE: Consulting and Separation Agreement 
 Dear Peter: 
 Further to our discussions, this letter sets forth the terms of the consulting and
separation agreement (the “Agreement”) between you and Patheon Pharmaceuticals Services Inc. (the “Company”). 

Pursuant to the Employment Agreement, dated December 31, 2009, between you and Patheon (the “Employment Agreement”), you are
currently employed as President, North American Operations. You have notified the Company of your desire to resign your position in order to pursue opportunities of an entrepreneurial nature. This new Agreement sets forth the Company’s and your
respective rights and obligations arising from your resignation from the Company and the terms and conditions pursuant to which you will perform transitional consulting services for the benefit of the Company. 

Any defined term used but not defined in this Agreement shall have the meaning ascribed to it in the Employment Agreement. 

1. Separation. 
 a. Separation Date. You acknowledge and agree that your resignation from employment and service as President, North American Operations is to be effective as of October 31, 2011
at 5:00 p.m. (the “Separation Date”), which will also serve as your COBRA qualifying event. 
 b.
Accrued Obligations. The Company shall pay, or cause to be paid, to you in a lump sum in cash the sum of: (i) that portion of the your Annual Base Salary earned but not previously paid through the Separation Date;
(ii) reimbursement of expenses incurred on or before the Separation Date in accordance with Section 3.7 of the Employment Agreement; and (iii) any accrued vacation pay, in each case to the extent not yet paid (the sum of the amounts

  
 

 

 
described in clauses (i), (ii), and (iii) shall be hereinafter referred to as the “Accrued Obligations”). The Accrued Obligations shall be paid on the next regular pay date
following the Separation Date consistent with the Company’s established payroll practices. 
 c. Other
Benefits. To the extent not yet paid or provided, the Company (or Patheon, as the case may be) shall pay or provide, or cause to be paid or provided, to you any other amounts or benefits required to be paid or provided or which you are
eligible to receive under any plan, program, policy or practice or contract or agreement of the Patheon Group (such other amounts and benefits shall be hereinafter referred to as the “Other Benefits”), in accordance with the terms
and normal procedures of each such plan, program, policy or practice or contract or agreement, based on earned, accrued or vested benefits through the Separation Date. 
 d. No Further Compensation. In accordance with Section 5.2 of the Employment Agreement, and except as otherwise expressly set forth in this Agreement, other than the obligations
to pay you the Accrued Obligations and the Other Benefits earned, accrued, or vested through the Separation Date, the Company shall have no further obligations to you to pay any compensation of any kind (including, without limitation, any bonus or
portion of a bonus that otherwise may have become due and payable to you with respect to the year in which such Separation Date occurs) or severance payment of any kind. This Agreement shall not compromise any right you may have to group health
continuation coverage under Sections 601 et seq. of ERISA (i.e., COBRA) nor shall it compromise any right to vested benefits accumulated under the express terms of any written ERISA-qualified benefit plan (e.g., a
 401(k) plan) subject to
the terms of the plan(s). 
 2. Consulting. 

a. Consulting Period. In consideration for your execution, non-revocation of, and compliance with the release
attached hereto as Appendix 1 and incorporated herein by reference, the Company agrees to retain you to perform services as a consultant to the Company from the Separation Date and continuing to the earlier of (i) October 31, 2012,
or (ii) the date upon which you secure a full-time employment engagement commensurate with your skills and experience (the “Consulting Period”) pursuant to the terms and conditions provided in this Agreement. 

b. Services. During the Consulting Period, you shall make yourself available to provide consulting services (the
“Services”) as requested by the Company. The Services shall consist of providing transitional assistance to bridge the arrival of new leadership for the North American Commercial Operations, including without limitation, handling
the transition of customer relationship management responsibilities and managing certain projects that are in process, briefing information as requested by the Company regarding any matters for which you had responsibility during your employment,
and such other special projects as may be assigned to you. You shall exercise the highest degree of professionalism and diligence in performing the Services. It is expected that you will be required to perform Services, on average, twenty four
(24) hours per week during the Consulting Period; however, the parties acknowledge that depending on the nature of the Services being performed the actual number of hours of Services performed may vary on a week-to-week basis. 

  

			
	 

	  	Page | 2

 c. Consulting Compensation. In consideration of the performance of the
Consulting Services hereunder, and your execution, non-revocation of, and compliance with the releases attached hereto, you will receive the following: 
 i. Consulting Fees. In consideration of your execution of the release attached hereto as Appendix 1, during the Consulting Period, the Company will pay you monthly consulting fees in an amount of
$24,583.33 per month, not to exceed an aggregate amount of $295,000.00 hereunder. The monthly consulting fees will be paid to you no later than the last day of each month during the Consulting Period. 

ii. Milestone Payment. Provided that you are still performing Services hereunder up to such time, an amount equal to the amount of the
bonus you would have received under the Company’s 2011 Leadership Incentive Plan had you remained actively employed by the Company at the time of plan payout (the “Milestone Payment”) will be payable to you by the Company upon
February 28, 2012. 
 iii. Performance Completion Payment. Provided that you are still performing Services hereunder up to
such time, and in consideration for your execution, non-revocation of, and compliance with another release in the form attached hereto as Appendix 2, an amount of $70,000.00 (the “Performance Completion Payment”) will be
payable to you by the Company upon the earlier of (i) October 31, 2012, or (ii) the date upon which you secure a full-time employment engagement commensurate with your skills and experience. 

iv. Expenses. The Company agrees to reimburse you for all actual, documented and out-of-pocket expenses incurred by you in connection
with the performance of the Services that have been approved in advance in writing by the Company. 
 d.
Termination. The Company may terminate this Agreement and the Services, effective upon written notice to you, in the event that you materially breach this Agreement, and such breach is incapable of cure, or with respect to a
material breach capable of cure, you do not cure such breach within fifteen (15) days after receipt of written notice of such breach. 
 3. Independent Contractor. You shall be an independent contractor of the Company, and this Agreement shall not be construed to create any association, partnership, joint venture, employee or agency
relationship between you and the Company for any purpose. You have no authority (and shall not hold yourself out as having authority) to bind the Company (or any member of the Patheon Group) and you shall not make any agreements or representations
on the Company’s (or any member of the Patheon Group’s) behalf without the Company’s prior written consent. Without limiting the foregoing, you will not be eligible under this Agreement to participate in any vacation, group medical or
life insurance, disability, profit sharing or retirement benefits or any other fringe benefits or benefit plans offered by the Company to its employees, and the Company will not be responsible for withholding or paying any income, payroll, Social
Security or other federal, state or local taxes, making any insurance contributions, including unemployment or disability, or obtaining worker’s compensation insurance on your behalf. You shall be responsible for, and shall indemnify the
Company against, all such taxes or contributions, including penalties and interest. 

  

			
	 

	  	Page | 3

 4. Confidentiality. The Confidentiality Undertaking, dated December 18, 2009,
between you and the Company shall apply mutatis mutandis to your performance under this Agreement. The Confidentiality Undertaking is attached hereto as Appendix 3 and incorporated herein by reference. For the purposes hereof, all
references to the “Agreement” in the Confidentiality Undertaking shall mean this Agreement. 
 5. Non-Competition;
Non-Solicitation. You acknowledge and agree that the Patheon Group is a business engaged in the sale of commercial pharmaceutical manufacturing capabilities and/or pharmaceutical development services, and during the Consulting Period, the
Patheon Group’s business may expand or change (“the Patheon Group’s Business”). Any such expansions and changes shall expand or change your obligations under this Agreement accordingly. The Patheon Group’s Business is
international in scope and without geographical limitation and the Patheon Group has valuable business relationships within its industry throughout the world. By virtue of your consulting engagement with the Company: (i) you have or will have
access to confidential and proprietary information of the Patheon Group, including valuable information about its business operations and methods and the persons with whom it does business in various locations throughout the world that is not
generally known to, or readily ascertainable by, the Patheon Group’s competitors, and you understand that the continued success of the Patheon Group depends upon the use and protection of a large body of confidential and proprietary
information, and (ii) you have has specialized knowledge of, and have received or will receive specialized training in, the Patheon Group’s Business. During the Consulting Period and for a period of twelve (12) months following the
termination of the Consulting Period for any reason (the “Non-compete Period”), you shall not engage in any of the following activities (except in connection with your duties for the Company): 

a. engage in any business activity that competes with the Patheon Group’s Business within the geographical areas set forth
below; 
 b. within the geographical areas set forth below, solicit or do business which is in competition with the
business engaged in by the Patheon Group, from or with persons or entities: (a) who are customers of the Patheon Group; (b) whom you or someone for whom you were responsible solicited, negotiated, contracted, serviced or had contact with
on the Patheon Group’s behalf; (c) who were customers of the Patheon Group at any time during the last year of your employment with the Patheon Group or during the Consulting Period; or (d) to whom the Patheon Group had made proposals
to do business at any time during the last year of your employment with the Company or during the Consulting Period; 
 c.
offer employment to or otherwise solicit for employment any employee or other person who had been employed by the Patheon Group during the last year of your employment with the Company or during the Consulting Period; provided,
however, that nothing contained herein shall be deemed to prohibit you from (i) conducting any general solicitation not specifically targeted at any such employee, and, for the avoidance of doubt, the hiring by you of any employee who
responds to such general advertising, or (ii) soliciting for employment or hiring any employee of the Patheon Group who was terminated by a member of the Patheon Group. 

  

			
	 

	  	Page | 4

 d. within the geographical areas set forth below, be employed (or otherwise engaged)
in (i) a management capacity, (ii) other capacity providing the same or similar services which you provided to the Patheon Group, or (iii) any capacity connected with competitive business activities, by any person or entity that
engages in the same, similar or otherwise competitive business as the Patheon Group; or 
 e. directly or indirectly take
any action which is materially detrimental or otherwise intended to be adverse to the Patheon Group’s goodwill, name, business relations, prospects and operations. 
 The restrictions set forth in this Section 5 apply to the following geographical areas: (i) the Research Triangle Park, North Carolina metropolitan area; (ii) the Cincinnati, Ohio
metropolitan area; (iii) any city, metropolitan area, county (or similar political subdivisions in foreign countries) in which the Patheon Group is located or does or, during your employment with the Company or during the Consulting Period, did
business; (iv) any city, metropolitan area, county (or similar political subdivisions in foreign countries) in which your services were provided, or for which your had responsibility, or in which you worked on Patheon Group projects, while
employed by the Company or during the Consulting Period. 
 If, at the time of enforcement of this Section 5, a court holds that the
restrictions stated herein are unreasonable under circumstances then existing, you agree that they be “blue-penciled” or rewritten by the court to the extent necessary to render them enforceable. 

6. Restrictive Covenant Remedies. In the event of a breach or threatened breach by you of any of the provisions of this
Agreement, you hereby consent and agree that the Company shall be entitled to seek, in addition to other available remedies, a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of
competent jurisdiction, without the necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting any bond or other security. The aforementioned equitable relief shall be in
addition to, not in lieu of, legal remedies, monetary damages or other available forms of relief. 
 7.
Assignment. 
 a. By the Company. To the extent permitted by applicable law, the Company may
assign this Agreement to any member of the Patheon Group, or to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company or Patheon.
This Agreement shall inure to the benefit of the Patheon Group and permitted successors and assigns. 
 b. By
Consultant. This Agreement is personal to you and you may not assign this Agreement or any part hereof. Any purported assignment by you shall be null and void from the initial date of purported assignment. 

8. Modification and Waiver. No provision of this Agreement may be amended or modified unless such amendment or modification
is agreed to in writing and signed by you and by an 

  

			
	 

	  	Page | 5

 
authorized signatory of the Company. No waiver by either of the Parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party
hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the Parties in exercising any right, power or privilege hereunder operate
as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power or privilege. No waiver shall be effective unless explicitly set forth in writing and signed by the party so waiving. 

9. Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such
invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. 

10. Confidentiality of this Agreement. You will hold the terms and conditions of this Agreement in strict
confidence. You have not and will not voluntarily disclose matters relating to the existence or the contents of this Agreement, including the amount of the monetary payment, to anyone other than (i) your spouse; and (ii) your attorneys,
accountants, financial advisors or healthcare providers for professional counseling. You also will take reasonable precautions to ensure that each of these persons maintain the confidentiality of the matters relating to the existence, terms and
conditions of this Agreement, including advising the person of the confidentiality provisions before I make any permitted disclosure. This provision does not preclude you from providing testimony if so mandated by court order or in an action to
enforce this Agreement. 
 11. Non-Disparagement. You will refrain from making statements, written or oral,
that disparage either the goodwill or reputation of the Company; its products or services; or its present/former directors, officers and employees. 
 12. Entire Agreement. Unless specifically provided herein, this Agreement and its accompanying Appendices contain all the understandings and representations between the Company and you
pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter. In the event of any inconsistency between
the statements in the body of this Agreement and the Employment Agreement, the statements in the body of this Agreement shall control. 
 13. Notices. 
 All notices and other communications hereunder shall
be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 
 If to you: 
 Peter T. Bigelow 

60 Diamond Road 

  

			
	 

	  	Page | 6

 Phoenixville, PA 19460-2780 

If to the Company: 
 Patheon Pharmaceuticals Services Inc. 
 4721 Emperor Blvd., Suite 200 

Durham, NC 27703 

Attention: Senior Vice President, Human Resources 
 with a copy to: 
 Patheon Pharmaceuticals Services Inc. 

4721 Emperor Blvd., Suite 200 
 Durham, NC 27703 
 Attention: Legal Department 

or to such other address as either party shall have furnished to the other in writing in accordance with this provision. Notice and communications shall
be effective when actually received by the addressee. 
 14. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of North Carolina without giving effect to any choice or conflict of law provision or rule (whether of the State of North Carolina or any other jurisdiction) that would cause the application of
laws of any jurisdiction other than those of the State of North Carolina. Any action or proceeding by either of the parties to enforce this Agreement shall be brought only in any state or federal court located in the state of North Carolina, county
of Wake. The parties hereby irrevocably submit to the jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such venue. 

15. Section 409A. This Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as
amended (Section 409A) or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an
event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a
short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of Section 409A, each instalment payment provided under this Agreement shall be treated as a separate payment. Any payments to be made
under this Agreement upon a termination of employment shall only be made upon a “separation from service” under Section 409A. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided
under this Agreement comply with Section 409A and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Employee on account of non-compliance with
Section 409A. 

  

			
	 

	  	Page | 7

 16. Counterparts. This Agreement may be executed in counterparts, each of
which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. 
 17.
Acknowledgment of Full Understanding. BY SIGNING THIS AGREEMENT, YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK
QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT. 
 IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date last written below. 
  

	
	 /s/ Peter T. Bigelow

	Peter T. Bigelow

 Date: 5 Oct. 2011 
  

			
	 “Company”

Patheon Pharmaceuticals Services Inc.

	
	 /s/ James Mullen

	By: James Mullen
	Title: Chief Executive Officer

 Date: 10/5/2011 

  

			
	 

	  	Page | 8

 Appendix 1 
 to 
 Consulting and Separation Agreement 

with 

Peter Bigelow 
 General Release in Consideration for Payments During Consulting Period 
 This General Release
(“Release”), dated as of October 31, 2011 confirms the following understandings and agreements between Peter Bigelow, an individual (“Executive”), and Patheon Pharmaceuticals Services Inc. (the
“Company”). 
 In consideration of the promises set forth in that certain Consulting and Separation Agreement between Executive
and the Company, effective as of October 31, 2011 (the “Agreement”), including without limitation the payments described in Section 2(c)(i) thereof, Executive agrees as follows: 

1. Release by Executive. 
 (a) For and in consideration of the Company retaining Executive for the Consulting Period described in the Agreement, including without limitation the payments described in Section 2(c)(i) thereof
(the “Consideration”), which is being provided in exchange for your execution of this Release and would not be provided absent your execution of this Release, Executive, for himself and his heirs, executors, administrators, assigns,
successors and agents (collectively, the “Executive’s Affiliates”) hereby fully and without limitation releases and forever discharges the Company and all other members of the Patheon Group and each of their respective agents,
representatives, shareholders, owners, officers, directors, employees, consultants, attorneys, auditors, accountants, investigators, affiliates, successors and assigns (collectively, the “Patheon Releasees”), both individually and
collectively, from any and all waivable rights, claims, demands, liabilities, actions, causes of action, damages, losses, costs, expenses and compensation, of whatever nature whatsoever, known or unknown, fixed or contingent, which Executive or any
of Executive’s Affiliates has or may have or may claim to have against any of the Patheon Releasees by reason of any matter, cause, or thing whatsoever, from the beginning of time to the date Executive signs this Release
(“Claims”), arising out of, based upon, or relating to his employment or the termination of his employment with the Company and/or his service as an officer of any of the Patheon Releasees, and/or any agreement or compensation
arrangement between Executive and any of the Patheon Releasees, to the maximum extent permitted by law. 
 (b) The Claims
released by Executive include, but are not limited to, any Claims arising out of or based on: Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family Medical Leave Act, Sections 1981
through 1988 of Title 42 of the United States Code, the Employee Retirement Income Security Act of 1974 (“ERISA”) (except for any vested benefits under any tax qualified benefit plan), the Immigration Reform and Control Act, the
Worker Adjustment and Retraining Notification Act, the Occupational Safety and Health Act, the Fair Credit Reporting Act, and the Sarbanes-Oxley Act of 2002 (in each case as the same may be amended from time to time); fraud, misrepresentation,
negligence, defamation, infliction of emotional distress or other tort, 

  

			
	 

	  	Page | 9

 
common law, breach of contract (whether express or implied, written or oral) or covenant, violation of public policy or wrongful termination; state or federal wage and hour laws; or any other
state or federal law, rule, or regulation dealing with the employment relationship, except those claims which may not be released herein as a matter of law. The released Claims also include any Claims by Executive for compensation, wages, back pay,
reinstatement or reemployment, bonuses, or benefits of any kind or any nature arising out of, based upon, or relating to his employment or the termination of his employment with the Company and/or his service as an officer of any of the Patheon
Releasees, and/or any agreement or compensation arrangement between Executive and any of the Patheon Releasees. 
 (c) Nothing
contained in this Section 1 or any other provision of this Release shall release or waive any right that Executive has to (i) the Consideration, (ii) any employee benefit Executive is entitled to receive from the Company pursuant to
any Company employee benefit plan or program, including any health claim or (iii) indemnification and/or reimbursement of expenses by the Company with respect to which Executive may be eligible as provided by law, the Company’s or any
member of the Patheon Group’s Certificates of Incorporation, Bylaws and any applicable directors and officers, errors & omissions, umbrella or general liability insurance policies, or any indemnification agreements, including the
Employment Agreement. Further, nothing contained in this Release shall restrict or inhibit any communications by Executive with the Equal Employment Opportunity Commission (“EEOC”) or any other government or law enforcement agency.

 2. Waiver of Applicable Release Laws. 
 (a) Executive understands and agrees that the release provided herein extends to all Claims released above whether known or unknown, suspected or unsuspected, which may be released as a matter of law.
Executive expressly waives and relinquishes any and all rights he may have under state law that prohibits the general release of unknown claims. 
 (b) It is the intention of each party through this Release to fully, finally and forever settle and release the Claims as set forth above. In furtherance of such intention, the release herein given shall
be and remain in effect as a full and complete release of such matters notwithstanding the discovery of any additional Claims or facts relating thereto. 
 3. No Filings. Executive represents that he has not filed any waivable lawsuits, claims, charges or complaints, which are pending as of the date hereof, against any of the Patheon Releasees with
any local, state or federal agency or court from the beginning of time to the date of execution of this Release, and he agrees that he shall not accept any award, damages, recovery or settlement from any proceeding brought by him or on his behalf
relating to his employment or the termination of his employment with the Company and/or his service as an officer of any of the Patheon Releasees or otherwise. 
 5. Cooperation Clause. To facilitate the orderly conduct of the Patheon Group, Executive agrees to cooperate, at no charge, with the Company’s reasonable requests for information or assistance
related to (i) the time of his employment, (ii) any investigations (including internal investigations) and audits of any member of the Patheon Group’s management’s current and past conduct and business and accounting practices
and (iii) any 

  

			
	 

	  	Page | 10

 
member of the Patheon Group’s defense of, or other participation in, any administrative, judicial, or other proceeding arising from any charge, complaint or other action which has been or
may be filed relating to the period during which Executive was employed by the Company. The Company will promptly reimburse Executive for his reasonable, customary and documented out-of-pocket business expenses in connection with the performance of
his duties under this Section 5. 
 6. Non-Admission of Liability. The parties understand and agree that neither the
furnishing of the Consideration nor the execution of this Release by the parties will constitute or be construed as an admission of any wrongdoing or liability whatsoever by any party. 

7. Severability. If any one or more of the provisions contained herein (or parts thereof), or the application thereof in any
circumstances, is held invalid, illegal or unenforceable in any respect for any reason, the validity and enforceability of any such provision in every other respect and of the remaining provisions hereof will not be in any way impaired or affected,
it being intended that all of the rights and privileges shall be enforceable to the fullest extent permitted by law. 
 8.
Entire Agreement. This Release, together with the Agreement dated October 31, 2011, including the restrictive covenants contained in paragraph 5 of that Agreement, represents the sole and entire agreement among the parties and, except as
expressly stated herein, supersedes all prior agreements, negotiations and discussions among the parties with respect to the subject matters contained herein. 
 9. Waiver. No waiver by any party hereto at any time of any breach of, or compliance with, any condition or provision of this Release to be performed by any other party hereto may be deemed a
waiver of similar or dissimilar provisions or conditions at the same time or at any prior or subsequent time. 
 10.
Counterparts. This Release may be executed in counterparts, each of which will be deemed to be an original as against any party that has signed it, but both of which together will constitute one and the same instrument. 

11. Miscellaneous Provisions. 
 (a) The parties represent that they have read this Release and fully understand all of its terms; that they have conferred with their attorneys, or have knowingly and voluntarily chosen not to confer with
their attorneys about this Release; that they have executed this Release without coercion or duress of any kind; and that they understand any rights that they have or may have, and they are signing this Release with full knowledge of any such
rights. 
 (b) Both parties have participated in the drafting of this Release with the assistance of counsel to the extent they
desired. The language in all parts of this Release must be in all cases construed simply according to its fair meaning and not strictly for or against any party. Whenever the context requires, all words used in the singular must be construed to have
been used in the plural, and vice versa, and each gender must include any other gender. The 

  

			
	 

	  	Page | 11

 
captions of the Sections of this Release are for convenience only and must not affect the construction or interpretation of any of the provision herein. 

(c) Each provision of this Release to be performed by a party hereto is both a covenant and condition, and is a material consideration
for the other party’s performance hereunder, and any breach thereof by the party will be a material default hereunder. All rights, remedies, undertakings, obligations, options, covenants, conditions and agreements contained in this Release are
cumulative and no one of them is exclusive of any other. Time is of the essence in the performance of this Release. 
 (d) Each
party acknowledges that no representation, statement or promise made by any other party, or by the agent or attorney of any other party, except for those in this Release, has been relied on by him or it in entering into this Release. 

(e) Unless expressly set forth otherwise, all references herein to a “day” are deemed to be a reference to a calendar day.
Unless expressly stated otherwise, cross-references herein refer to provisions within this Release and are not references to any other document. 
 (f) Each party to this Release will cooperate fully in the execution of any and all other documents and in the completion of any additional actions that may be necessary or appropriate to give full force
and effect to the terms and intent of this Release. 
 EACH OF THE PARTIES ACKNOWLEDGES THAT HE/IT HAS READ THIS AGREEMENT, UNDERSTANDS IT AND
IS VOLUNTARILY ENTERING INTO IT, AND THAT IT INCLUDES A WAIVER OF THE RIGHT TO A TRIAL BY JURY, AND, WITH RESPECT TO EXECUTIVE, HE UNDERSTANDS THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS OTHER THAN AS PROVIDED FOR HEREIN.
EXECUTIVE ACKNOWLEDGES THAT HE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF HIS CHOICE BEFORE SIGNING THIS RELEASE. 

IN WITNESS WHEREOF, the parties have executed this Release as of the dates indicated below. 

 

	
	“Executive”
	
	  

	 Peter T. Bigelow

	 Date:

	
	“Company”
	Patheon Pharmaceuticals Services Inc.
	
	  

	By: James Mullen
	Title: Chief Executive Officer
	Date:

  

			
	 

	  	Page | 12

 Appendix 2 
 to 
 Consulting and Separation Agreement 

with 

Peter Bigelow 
 General Release in Consideration for Performance Completion Payment at Conclusion of 

Consulting Period 
 This General
Release (“Release”), dated as of
                                        ,
confirms the following understandings and agreements between Peter Bigelow, an individual (“Executive”), and Patheon Pharmaceuticals Services Inc. (the “Company”). 

In consideration of the promises set forth in that certain Consulting and Separation Agreement between Executive and the Company, effective as of
October 31, 2011 (the “Agreement”), including without limitation the payments described in Section 2(c)(iii) thereof, Executive agrees as follows: 
 1. Release by Executive. 
 (d) For and in consideration of the Company
entering the Agreement, including without limitation the Performance Completion Payment described in Section 2(c)(iii) thereof (the “Consideration”), which is being provided in exchange for your execution of this Release and
would not be provided absent your execution of this Release, Executive, for himself and his heirs, executors, administrators, assigns, successors and agents (collectively, the “Executive’s Affiliates”) hereby fully and without
limitation releases and forever discharges the Company and all other members of the Patheon Group and each of their respective agents, representatives, shareholders, owners, officers, directors, employees, consultants, attorneys, auditors,
accountants, investigators, affiliates, successors and assigns (collectively, the “Patheon Releasees”), both individually and collectively, from any and all waivable rights, claims, demands, liabilities, actions, causes of action,
damages, losses, costs, expenses and compensation, of whatever nature whatsoever, known or unknown, fixed or contingent, which Executive or any of Executive’s Affiliates has or may have or may claim to have against any of the Patheon Releasees
by reason of any matter, cause, or thing whatsoever, from the beginning of time to the date Executive signs this Release (“Claims”), arising out of, based upon, or relating to his employment or the termination of his employment with
the Company and/or his service as an officer of any of the Patheon Releasees, and/or his service as an independent contractor under the terms of the Agreement, and/or any agreement or compensation arrangement between Executive and any of the Patheon
Releasees, to the maximum extent permitted by law. 
 (e) The Claims released by Executive include, but are not limited to, any
Claims arising out of or based on: Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family Medical Leave Act, Sections 1981 through 1988 of Title 42 of the United States Code, the
Employee Retirement Income Security Act of 1974 (“ERISA”) (except for any vested benefits under any tax qualified benefit plan), the Immigration Reform and Control Act, the Worker Adjustment and Retraining Notification Act, the
Occupational Safety and Health Act, the Fair Credit Reporting Act, and the Sarbanes-Oxley 

  

			
	 

	  	Page | 13

 
Act of 2002 (in each case as the same may be amended from time to time); fraud, misrepresentation, negligence, defamation, infliction of emotional distress or other tort, common law, breach of
contract (whether express or implied, written or oral) or covenant, violation of public policy or wrongful termination; state or federal wage and hour laws; or any other state or federal law, rule, or regulation dealing with the employment
relationship, except those claims which may not be released herein as a matter of law. The released Claims also include any Claims by Executive for compensation, wages, back pay, reinstatement or reemployment, bonuses, or benefits of any kind or any
nature arising out of, based upon, or relating to his employment or the termination of his employment with the Company and/or his service as an officer of any of the Patheon Releasees, and/or any agreement or compensation arrangement between
Executive and any of the Patheon Releasees. 
 (f) Nothing contained in this Section 1 or any other provision of this
Release shall release or waive any right that Executive has to (i) the Consideration, (ii) any employee benefit Executive is entitled to receive from the Company pursuant to any Company employee benefit plan or program, including any
health claim or (iii) indemnification and/or reimbursement of expenses by the Company with respect to which Executive may be eligible as provided by law, the Company’s or any member of the Patheon Group’s Certificates of
Incorporation, Bylaws and any applicable directors and officers, errors & omissions, umbrella or general liability insurance policies, or any indemnification agreements, including the Employment Agreement. Further, nothing contained in this
Release shall restrict or inhibit any communications by Executive with the Equal Employment Opportunity Commission (“EEOC”) or any other government or law enforcement agency. 

2. Waiver of Applicable Release Laws. 
 (c) Executive understands and agrees that the release provided herein extends to all Claims released above whether known or unknown, suspected or unsuspected, which may be released as a matter of law.
Executive expressly waives and relinquishes any and all rights he may have under state law that prohibits the general release of unknown claims. 
 (d) It is the intention of each party through this Release to fully, finally and forever settle and release the Claims as set forth above. In furtherance of such intention, the release herein given shall
be and remain in effect as a full and complete release of such matters notwithstanding the discovery of any additional Claims or facts relating thereto. 
 3. No Filings. Executive represents that he has not filed any waivable lawsuits, claims, charges or complaints, which are pending as of the date hereof, against any of the Patheon Releasees with
any local, state or federal agency or court from the beginning of time to the date of execution of this Release, and he agrees that he shall not accept any award, damages, recovery or settlement from any proceeding brought by him or on his behalf
relating to his employment or the termination of his employment with the Company and/or his service as an officer of any of the Patheon Releasees or otherwise. 
 6. Cooperation Clause. To facilitate the orderly conduct of the Patheon Group, Executive agrees to cooperate, at no charge, with the Company’s reasonable requests for information or assistance
related to (i) the time of his employment, (ii) any investigations 

  

			
	 

	  	Page | 14

 
(including internal investigations) and audits of any member of the Patheon Group’s management’s current and past conduct and business and accounting practices and (iii) any member
of the Patheon Group’s defense of, or other participation in, any administrative, judicial, or other proceeding arising from any charge, complaint or other action which has been or may be filed relating to the period during which Executive was
employed by the Company. The Company will promptly reimburse Executive for his reasonable, customary and documented out-of-pocket business expenses in connection with the performance of his duties under this Section 5. 

6. Non-Admission of Liability. The parties understand and agree that neither the furnishing of the Consideration nor the execution
of this Release by the parties will constitute or be construed as an admission of any wrongdoing or liability whatsoever by any party. 
 7. Severability. If any one or more of the provisions contained herein (or parts thereof), or the application thereof in any circumstances, is held invalid, illegal or unenforceable in any respect
for any reason, the validity and enforceability of any such provision in every other respect and of the remaining provisions hereof will not be in any way impaired or affected, it being intended that all of the rights and privileges shall be
enforceable to the fullest extent permitted by law. 
 8. Entire Agreement. This Release, together with the Agreement
dated October 31, 2011, including the restrictive covenants contained in paragraph 5 of that Agreement, represents the sole and entire agreement among the parties and, except as expressly stated herein, supersedes all prior agreements,
negotiations and discussions among the parties with respect to the subject matters contained herein. 
 9. Waiver. No
waiver by any party hereto at any time of any breach of, or compliance with, any condition or provision of this Release to be performed by any other party hereto may be deemed a waiver of similar or dissimilar provisions or conditions at the same
time or at any prior or subsequent time. 
 10. Counterparts. This Release may be executed in counterparts, each of which
will be deemed to be an original as against any party that has signed it, but both of which together will constitute one and the same instrument. 
 11. Miscellaneous Provisions. 
 (g) The parties represent that they have
read this Release and fully understand all of its terms; that they have conferred with their attorneys, or have knowingly and voluntarily chosen not to confer with their attorneys about this Release; that they have executed this Release without
coercion or duress of any kind; and that they understand any rights that they have or may have, and they are signing this Release with full knowledge of any such rights. 
 (h) Both parties have participated in the drafting of this Release with the assistance of counsel to the extent they desired. The language in all parts of this Release must be in all cases construed
simply according to its fair meaning and not strictly for or against any party. Whenever the context requires, all words used in the singular must be construed to have 

  

			
	 

	  	Page | 15

 
been used in the plural, and vice versa, and each gender must include any other gender. The captions of the Sections of this Release are for convenience only and must not affect the construction
or interpretation of any of the provision herein. 
 (i) Each provision of this Release to be performed by a party hereto is
both a covenant and condition, and is a material consideration for the other party’s performance hereunder, and any breach thereof by the party will be a material default hereunder. All rights, remedies, undertakings, obligations, options,
covenants, conditions and agreements contained in this Release are cumulative and no one of them is exclusive of any other. Time is of the essence in the performance of this Release. 

(j) Each party acknowledges that no representation, statement or promise made by any other party, or by the agent or attorney of any
other party, except for those in this Release, has been relied on by him or it in entering into this Release. 
 (k) Unless
expressly set forth otherwise, all references herein to a “day” are deemed to be a reference to a calendar day. Unless expressly stated otherwise, cross-references herein refer to provisions within this Release and are not references to
any other document. 
 (l) Each party to this Release will cooperate fully in the execution of any and all other documents and
in the completion of any additional actions that may be necessary or appropriate to give full force and effect to the terms and intent of this Release. 
 EACH OF THE PARTIES ACKNOWLEDGES THAT HE/IT HAS READ THIS AGREEMENT, UNDERSTANDS IT AND IS VOLUNTARILY ENTERING INTO IT, AND THAT IT INCLUDES A WAIVER OF THE RIGHT TO A TRIAL BY JURY, AND, WITH RESPECT TO
EXECUTIVE, HE UNDERSTANDS THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS OTHER THAN AS PROVIDED FOR HEREIN. EXECUTIVE ACKNOWLEDGES THAT HE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF HIS CHOICE
BEFORE SIGNING THIS RELEASE. 
 IN WITNESS WHEREOF, the parties have executed this Release as of the dates indicated below. 

 

	
	“Executive”
	
	  

	Peter T. Bigelow
	Date:
	
	“Company”
	Patheon Pharmaceuticals Services Inc.
	
	  

	By: James Mullen
	Title: Chief Executive Officer
	Date:

  

			
	 

	  	Page | 16

 Appendix 3 
 Confidentiality Undertaking 
  

 
 CONFIDENTIALITY UNDERTAKING

 In consideration of Peter T. Bigelow (the “Executive”) accepting an employment agreement between the Executive and Patheon
Pharmaceuticals Services Inc. dated December 18, 2009 (the “Agreement”) to which this Confidentiality Undertaking is attached as Schedule B, the Executive undertakes and covenants with the Affiliated Group (as defined in the
Agreement) as follows: 
  

	1.	CONFIDENTIAL INFORMATION 

  

	1.1	Confidential Information 

 The Executive
acknowledges that all information and facts relating to the business and affairs of the Affiliated Group and its customers, including, without limitation, trade secrets, data, notes, marketing plans, sales patterns, and private corporate and
financial information (the “Confidential Information”) is confidential and proprietary to the Affiliated Group and a valuable trade secret of the Affiliated Group, disclosure of which could severely damage the economic interests of
the Affiliated Group. Confidential Information includes, without limitation, any document, work, instrument or other medium assembled or composed by the Executive which contains Confidential Information. 

 

	1.2	Non-Disclosure of Confidential Information 

The Executive shall not, either during the term of the Agreement or at any time thereafter. use or disclose, directly or indirectly, any of such
Confidential Information to any person outside the Affiliated Group, except where such disclosure is necessary for the proper and bona fide execution of the Executive’s duties under the Agreement, without the prior written consent of the
Affiliated Group. The Executive’s obligation not to use or disclose Confidential Information without prior written consent shall continue to apply after the Executive has ceased to be an employee of the Affiliated Group until such time as the
Confidential Information becomes public knowledge through no fault of the Executive. The Affiliated Group will have full right, title and authority to deal in and with the proprietary rights and the Confidential Information notwithstanding any other
provision of the Agreement or the termination thereof for any reason whatsoever. The Executive acknowledges and agrees that the restrictions contained in this Article 1 are reasonable in the circumstances in order to protect the business of the
Affiliated Group. 
  

	1.3	Return of Confidential Information 

Confidential Information and the documents, works, instruments or other media containing Confidential Information shall remain the property of the
Affiliated Group and be returned to the Affiliated Group upon request or immediately following termination of the Agreement for any reason whatsoever. 
  

	2.	INVENTIONS 

  

	2.1	Inventions 

 Subject to Section 2.2,
the Executive agrees that all discoveries, improvements, designs, ideas or inventions made or conceived, in whole or in part, by the Executive during the term of the Agreement or within three years following termination of the Agreement for any
reason whatsoever (the “Inventions”) shall be the sole property of the Affiliated Group. The Executive shall: 
  

	 	(a)	promptly disclose and describe all such Inventions in writing to the Affiliated Group; 

 

	 	(b)	assign, and the Executive does hereby assign, to the Affiliated Group, without further compensation, all of the Executive’s rights, title and interest in and to
such Inventions and to all applications for letters of patent, copyrights, industrial design or other forms of protection granted for such Inventions throughout the world; 

  

			
	 

	  	Page | 17

	 	(c)	deliver promptly to the Affiliated Group, upon request and in the form and manner prescribed by the Affiliated Group (without charge to the Affiliated Group but at the
Affiliated Group’s expense) the written instruments described in paragraph (b) and perform such acts as deemed necessary by the Affiliated Group to obtain and maintain such instruments and to transfer all rights and title thereto to the
Affiliated Group; and 

  

	 	(d)	give all assistance that may be required by the Affiliated Group to enable it to protect or exploit the Inventions in any country of the world.

 The Executive does hereby waive in whole any moral rights that the Executive may have in each of the Inventions and any part or
parts thereof, including, but not limited to, the right to the integrity of the Inventions, the right to be associated with the Inventions as its author by name or under a pseudonym and the right to remain anonymous. 

 

	2.2	Excluded Inventions 

 The provisions of
Section 2.1 shall not apply to Inventions which fulfill all of the following criteria: 
  

	 	(a)	Inventions for which no equipment, supplies, facility or Confidential Information belonging to the Affiliated Group were used; and 

 

	 	(b)	Inventions that do not relate to the business of the Affiliated Group or to the Affiliated Group’s actual or demonstrably anticipated processes, research or
development which the Executive had access to or knowledge of; and 

  

	 	(c)	Inventions that do not result from any work performed by the Executive for the Affiliated Group. 

 

	3.	GENERAL 

 This Confidentiality Undertaking
shall be governed and construed in accordance with the laws of North Carolina applicable therein. Nothing herein shall be construed so as to limit any obligations owed by you to the Affiliated Group as a matter of common law. The Executive
acknowledges that the business of the Affiliated Group cannot be properly protected from 
 adverse consequences of the Executive’s actions
other than by the restrictions set forth in this Undertaking and the Agreement. The Affiliated Group, in addition to any other right or relief to which it may be entitled, shall be entitled to an injunction restricting further breaches of this
Undertaking or the Agreement. This Confidentiality Undertaking shall survive the termination of the Agreement and the Executive’s employment thereunder. 
 IN WITNESS WHEREOF this Confidentiality Undertaking has been executed by the undersigned on this 07 day of Jan, 2010. 
  

							
	SIGNED, SEALED AND DELIVERED	 	)	 		 	
	 in the presence of
	 	)	 		 	
		 	)	 		 	
	  
	 	)	 	   /s/ Peter T. Bigelow
	 	
	Name of Witness:	 		 	   Peter T. Bigelow
	 	

  

			
	 

	  	Page | 18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]